Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
303 Results for "
MDCKII-MDR1 P-gp
" in MedChemExpress (MCE) Product Catalog:
Products (303)
303 Results for "MDCKII-MDR1 P-gp" in MCE Product Catalog:
Cat. No.: HY-132189
CAS No.: 197509-46-9
Target:
Research Areas:
Laniquidar is a non-competitive P-gp inhibitor with an IC50 of 0.51 μM. Laniquidar binds to the P-gp transporter with high affinity and exhibits low activity as a substrate. Laniquidar is applicable to epilepsy-related research [1].
Synonyms: 1,2-Didecanoyl-sn-glycero-3-phosphocholine
Target:
Research Areas:
1,2-Didecanoyl PC (1,2-Didecanoyl-sn-glycero-3-phosphocholine) is an orally effective medium-chain saturated phospholipid with well-defined P-gp inhibitory activity and membrane-modulating functions. As a functional excipient/absorption enhancer, 1,2-Didecanoyl PC is particularly suitable for oral formulations of P-gp substrates (e.g., Ritonavir (HY-90001)) [1].
Cat. No.: HY-W035709
CAS No.: 485-65-4
Synonyms: Dihydrocinchonine
Target:
Target:
Research Areas:
Penicillin G Procaine hydrate (PGP hydrate) is a β-lactam antibiotic and sustained-release formulation. Penicillin G procaine (hydrate) hydrolyzes in vivo to release penicillin G (HY-N7139) and Procaine (HY-B0546), thereby delaying the absorption of penicillin G [1].
Target:
Research Areas:
PGP-4008 is a specific P-glycoprotein (Pgp) inhibitor. PGP-4008 inhibits tumor growth in a murine syngeneic Pgp-mediated multiple agent resistance (MDR) solid tumor model when given in combination with Doxorubicin [1].
Cat. No.: HY-173162
CAS No.: 86383-89-3
Target:
Research Areas:
GPV0057 (Compound 5d) is a selective and potent P-glycoprotein (P-gp) inhibitor. GPV0057 is also a selective potassium channel Kir2.1 activator. GPV0057 competitively binds to the substrate-binding site of P-gp, inhibiting ATP-dependent drug efflux to reverse multidrug resistance in tumor cells. GPV0057 can also stabilizes the open state of Kir2.1 and promotes potassium ion influx. GPV0057 is promising for research of tumors with high P-gp expression, Kir2.1-deficient diseases such as heart failure and Andersen-Tawil Syndrome [1] .
Cat. No.: HY-B0777S
Synonyms: CL-301423-d3
Target:
Research Areas:
P-gp inhibitor 1 is a novel inhibitor reversing P-glycoprotein-mediated multidrug resistance.
Cat. No.: HY-144366
CAS No.: 2766451-11-8
Target:
Research Areas:
P-gp inhibitor 3 is an effective P-glycoprotein (P-gp) inhibitor. P-gp inhibitor 3 inhibits the efflux function of P-gp by activating P-gp ATPase. P-gp inhibitor 3 has relatively stronger multidrug resistance (MDR) reversal ability and enhances the anti-tumor activity of Paclitaxel [1].
Target:
Research Areas:
YS-370 (compound 44) is a potent, high selective, and orally active inhibitor of P-glycoprotein (P-gp). YS-370 stimulates the P-gp ATPase activity and has moderate inhibition against CYP3A4. YS-370 effectively reverses multidrug resistance (MDR) to paclitaxel and colchicine in SW620/AD300 and HEK293T-ABCB1 cells. YS-370 in combination with paclitaxel achieves much stronger antitumor activity [1].
Cat. No.: HY-178349
Target:
Research Areas:
P-gp inhibitor 30 is a potent P-gp inhibitor that reverses multidrug resistance in breast cancer by sensitizing resistant cells to Doxorubicin (ADM) (HY-15142). P-gp inhibitor 30 promotes apoptosis, induces autophagy, and suppresses proliferation, migration, and invasion of drug-resistant breast cancer cells when combined with ADM. P-gp inhibitor 30 inhibits breast tumor growth both in vitro and in vivo. P-gp inhibitor 30 can be used for drug-resistant breast cancer research [1].
Cat. No.: HY-175838
CAS No.: 2918249-59-7
Target:
Research Areas:
P-gp-IN-32 is a P-glycoprotein (P-gp) inhibitor. P-gp-IN-32 exhibits low cytotoxicity and potent multidrug resistance (MDR) reversal activity against Doxorubicin (HY-15142A) in MCF7/ADR cells (IC50 = 0.11 μM, reversal fold (RF) = 215.9). P-gp-IN-32 can bind to P-gp directly, induce a conformation change of P-gp and inhibit the efflux function. P-gp-IN-32 can be used for the research of cancer, such as breast cancer [1].
Cat. No.: HY-146391
CAS No.: 2652001-05-1
Target:
Research Areas:
P-gp inhibitor 4 (Compound 8b) is a selective P-glycoprotein modulator with an EC50 of 94 nM. P-gp inhibitor 4 increases agent transport across gastro-intestinal barrier and recovers doxorubicin toxicity in multidrug resistant cancer cells [1].
Cat. No.: HY-149277
CAS No.: 1807320-40-6
Target:
Research Areas:
FM04 is a potent P-glycoprotein (P-gp) inhibitor (EC50=83 nM). FM04 inhibits P-gp in 2 mechanism: (1)FM04 binds to Q1193, followed by interacting with the functionally critical residues H1195 and T1226; or (2)FM04 binds to I1115 (a functionally critical residue itself), disrupting the R262-Q1081-Q1118 interaction pocket and uncoupling ICL2-NBD2 interaction and thereby inhibiting P-gp [1].
Cat. No.: HY-W001601
CAS No.: 57982-78-2
Target:
Research Areas:
Budipine is an anti-parkinson agent. Budipine also is a substrate of P-glycoprotein (P-gp), is mediated the uptake into the brain by P-gp. Budipine also is N-methyl-d-aspartate (NMDA) antagonist, and has indirect dopaminergic effects through an improved dopamine release, the inhibition of monoamine oxidase type B (MAO-B). Budipine can be used for the research of CNS disorders include Parkinson disease [1].
Cat. No.: HY-110377
CAS No.: 1992047-62-7
Synonyms: XR9576 dihydrochloride
Target:
Research Areas:
Tariquidar dihydrochloride (XR9576 dihydrochloride) is a potent and specific inhibitor of P-glycoprotein (P-gp) with the high affinity (Kd=5.1 nM) [1].
Cat. No.: HY-176193
Target:
Research Areas:
P-gp modulator-7 (Compound 9e) is a P-glycoprotein (P-gp) inhibitor. P-gp modulator-7 occupies the channel entrance of P-gp with a unique T-shaped configuration, hindering the peristaltic extrusion mechanism of transmembrane domains TM12 and TM9, thereby inhibiting P-gp from pumping drugs out of cells and reversing the multidrug resistance (MDR) of tumor cells. P-gp modulator-7 is promising for research of cancers [1].
Cat. No.: HY-162040
CAS No.: 2556388-58-8
Target:
Research Areas:
P-gp inhibitor 17 (compound 2g) is a P-gp inhibitor directly interacted with the transmembrane domain of P-gp. P-gp inhibitor 17 can be used for P-gp-mediated multidrug-resistant in tumor cells study [1].
Cat. No.: HY-157483
Target:
Research Areas:
P-gp inhibitor 18 (compound 6G) is a potent inhibitor of P-gp. P-gp inhibitor 18 inhibits rhodamine 123 efflux in the P-gp overexpressed leukemia cells, K562/Dox [1].
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
